Chemotherapy resumption in breast cancer patient after COVID-19
Abstract Background While many studies have verified the effect of recent anti-cancer treatment in patients with COVID-19, there are no data on the optimal time for cancer treatment resumption, as well as the safety of chemotherapy in COVID-19 patients. As many cancer patients are recovering from CO...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Japan Surgical Society
2021-07-01
|
| Series: | Surgical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40792-021-01253-0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849251460223598592 |
|---|---|
| author | Julian Horiguchi Ayako Nakashoji Naoki Kawahara Akira Matsui Takayuki Kinoshita |
| author_facet | Julian Horiguchi Ayako Nakashoji Naoki Kawahara Akira Matsui Takayuki Kinoshita |
| author_sort | Julian Horiguchi |
| collection | DOAJ |
| description | Abstract Background While many studies have verified the effect of recent anti-cancer treatment in patients with COVID-19, there are no data on the optimal time for cancer treatment resumption, as well as the safety of chemotherapy in COVID-19 patients. As many cancer patients are recovering from COVID-19, there is an urgent need for reliable clinical information. Herein, we report a case of invasive ductal carcinoma in which we were able to successfully resume chemotherapy after infection with SAR-CoV-2. Case presentation The patient was a 38-year-old non-smoking Japanese woman with no significant medical history. She had fever on days 5 and 6 of her second course of adjuvant FEC therapy, and on day 7, she tested positive for SARS-CoV-2 by RT-PCR. She was hospitalized for 11 days. We resumed the therapy on day 25 after discharge, as she had no remaining clinical symptoms. The patient completed four courses of the initial chemotherapy without any major adverse events nor the recurrence of COVID-19, and subsequently completed four courses of docetaxel as her second regimen therapy. Conclusions Evaluating the risk for each patient is essential when resuming anti-cancer therapy in cancer patient’s post-COVID-19. |
| format | Article |
| id | doaj-art-a489696203e347bcbf10ff1ca060c8c8 |
| institution | Kabale University |
| issn | 2198-7793 |
| language | English |
| publishDate | 2021-07-01 |
| publisher | Japan Surgical Society |
| record_format | Article |
| series | Surgical Case Reports |
| spelling | doaj-art-a489696203e347bcbf10ff1ca060c8c82025-08-20T03:56:55ZengJapan Surgical SocietySurgical Case Reports2198-77932021-07-01711510.1186/s40792-021-01253-0Chemotherapy resumption in breast cancer patient after COVID-19Julian Horiguchi0Ayako Nakashoji1Naoki Kawahara2Akira Matsui3Takayuki Kinoshita4Department of Surgery, National Hospital Organization Tokyo Medical CenterDepartment of Breast Surgery, National Hospital Organization Tokyo Medical CenterDepartment of Surgery, National Hospital Organization Tokyo Medical CenterDepartment of Breast Surgery, National Hospital Organization Tokyo Medical CenterDepartment of Breast Surgery, National Hospital Organization Tokyo Medical CenterAbstract Background While many studies have verified the effect of recent anti-cancer treatment in patients with COVID-19, there are no data on the optimal time for cancer treatment resumption, as well as the safety of chemotherapy in COVID-19 patients. As many cancer patients are recovering from COVID-19, there is an urgent need for reliable clinical information. Herein, we report a case of invasive ductal carcinoma in which we were able to successfully resume chemotherapy after infection with SAR-CoV-2. Case presentation The patient was a 38-year-old non-smoking Japanese woman with no significant medical history. She had fever on days 5 and 6 of her second course of adjuvant FEC therapy, and on day 7, she tested positive for SARS-CoV-2 by RT-PCR. She was hospitalized for 11 days. We resumed the therapy on day 25 after discharge, as she had no remaining clinical symptoms. The patient completed four courses of the initial chemotherapy without any major adverse events nor the recurrence of COVID-19, and subsequently completed four courses of docetaxel as her second regimen therapy. Conclusions Evaluating the risk for each patient is essential when resuming anti-cancer therapy in cancer patient’s post-COVID-19.https://doi.org/10.1186/s40792-021-01253-0COVID-19Severe acute respiratory syndrome coronavirus 2ResumptionBreast cancerChemotherapyCase report |
| spellingShingle | Julian Horiguchi Ayako Nakashoji Naoki Kawahara Akira Matsui Takayuki Kinoshita Chemotherapy resumption in breast cancer patient after COVID-19 Surgical Case Reports COVID-19 Severe acute respiratory syndrome coronavirus 2 Resumption Breast cancer Chemotherapy Case report |
| title | Chemotherapy resumption in breast cancer patient after COVID-19 |
| title_full | Chemotherapy resumption in breast cancer patient after COVID-19 |
| title_fullStr | Chemotherapy resumption in breast cancer patient after COVID-19 |
| title_full_unstemmed | Chemotherapy resumption in breast cancer patient after COVID-19 |
| title_short | Chemotherapy resumption in breast cancer patient after COVID-19 |
| title_sort | chemotherapy resumption in breast cancer patient after covid 19 |
| topic | COVID-19 Severe acute respiratory syndrome coronavirus 2 Resumption Breast cancer Chemotherapy Case report |
| url | https://doi.org/10.1186/s40792-021-01253-0 |
| work_keys_str_mv | AT julianhoriguchi chemotherapyresumptioninbreastcancerpatientaftercovid19 AT ayakonakashoji chemotherapyresumptioninbreastcancerpatientaftercovid19 AT naokikawahara chemotherapyresumptioninbreastcancerpatientaftercovid19 AT akiramatsui chemotherapyresumptioninbreastcancerpatientaftercovid19 AT takayukikinoshita chemotherapyresumptioninbreastcancerpatientaftercovid19 |